Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 6:12 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2353–2376 of 33,183 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Placebo Clear all

Conditions: Pulmonary Disease, Chronic Obstructive
Interventions: Umeclidinium, Umeclidinium matching placebo, Tiotropium, Tiotropium matching placebo; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 40 Years and older
Enrollment: 1,017 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Spartanburg, South Carolina

Conditions: Fibromyalgia
Interventions: Ibutamoren Mesylate (MK-0677); Drug
Lead sponsor: Bennett, Robert, M.D.; Individual
Eligibility: 30 Years to 65 Years · Female only
Enrollment: 64 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2008
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Lymphedema
Interventions: ubenimex, placebo; Drug · Other
Lead sponsor: Eiger BioPharmaceuticals; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 3
States / cities: Stanford, California • Orlando, Florida • Columbus, Ohio

Conditions: Peyronie's Disease
Interventions: Subjects Previously Treated with AA4500; Drug
Lead sponsor: Endo USA Inc., a Keenova Therapeutics Company; Industry
Eligibility: 18 Years to 90 Years · Male only
Enrollment: 184 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 30
States / cities: Anchorage, Alaska • Burbank, California • Laguna Hills, California + 27 more

Conditions: Major Depressive Disorder
Interventions: Agomelatine (AGO178C), Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 589 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 43
States / cities: Birmingham, Alabama • Costa Mesa, California • El Centro, California + 39 more

Conditions: Rheumatoid Arthritis
Interventions: Veltuzumab; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 8
States / cities: La Mesa, California • Los Angeles, California • Upland, California + 5 more

Conditions: Pain Management
Interventions: MK-6916, Hydrocodone/acetaminophen (HB/APAP), MK-6916 Placebo, Rescue Medication; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 380 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 9
States / cities: Miami, Florida • Tampa, Florida • Atlanta, Georgia + 6 more

Conditions: Bronchopulmonary Dysplasia, Respiratory Distress Syndrome, Infant, Newborn, Infant, Low Birth Weight, Infant, Small for Gestational Age, Infant, Premature
Interventions: Minimal mechanical ventilation management, Routine mechanical ventilation management, Dexamethasone, Placebo; Procedure · Drug
Lead sponsor: NICHD Neonatal Research Network; Network
Eligibility: 5 Minutes to 10 Days
Enrollment: 220 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1998 – 2002
U.S. locations: 13
States / cities: Birmingham, Alabama • Palo Alto, California • New Haven, Connecticut + 10 more

Conditions: Toxicant Induced Chronic Multisymptom Illness and Associated Symptoms and Comorbidities
Interventions: Ubiquinone 100 mg Oral Soft Gel, Placebo; Drug
Lead sponsor: University of California, San Diego; Other
Eligibility: 18 Years to 65 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: La Jolla, California

Conditions: Migraine Headache
Interventions: Inhaled Placebo, Inhaled Loxapine 1.25 mg, Inhaled Loxapine 2.5 mg; Drug
Lead sponsor: Alexza Pharmaceuticals, Inc.; Other
Eligibility: 18 Years to 65 Years
Enrollment: 366 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009
U.S. locations: 3
States / cities: Springfield, Missouri • Mount Vernon, New York • East Providence, Rhode Island

Conditions: Bilateral Primary Osteoarthritis of Knee
Interventions: Autologous Bone Marrow Aspirate Concentrate, Sterile saline; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 99 Years
Enrollment: 25 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2016
U.S. locations: 1
States / cities: Jacksonville, Florida

Conditions: Epidermolysis Bullosa
Interventions: allo-APZ2-OTS, Placebo; Drug
Lead sponsor: RHEACELL GmbH & Co. KG; Industry
Eligibility: 6 Months and older
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 2
States / cities: Aurora, Colorado • Minneapolis, Minnesota

Conditions: Healthy
Interventions: CD388 Injection, Saline placebo; Combination Product · Drug
Lead sponsor: Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA); Industry
Eligibility: 18 Years to 65 Years
Enrollment: 28 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Cypress, California

Conditions: Alzheimer Disease, Healthy
Interventions: GSI-136, Placebo; Drug · Other
Lead sponsor: Wyeth is now a wholly owned subsidiary of Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 80 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008
U.S. locations: 1
States / cities: New York, New York

Conditions: Menorrhagia
Interventions: Naproxen, Placebo; Drug
Lead sponsor: University of Washington; Other
Eligibility: 18 Years to 49 Years · Female only
Enrollment: 34 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2017
U.S. locations: 5
States / cities: Chicago, Illinois • Seattle, Washington

Conditions: Methamphetamine or Cocaine Dependence
Interventions: Doxazosin extended release; Drug
Lead sponsor: University of Arkansas; Other
Eligibility: 18 Years to 55 Years
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 1
States / cities: Little Rock, Arkansas

Conditions: Sleep Apnea, Opioid Use, Sleep Disordered Breathing
Interventions: Hyperoxia, Acetazolamide; Other · Drug
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years to 89 Years
Enrollment: 150 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2027
U.S. locations: 1
States / cities: Detroit, Michigan

Conditions: Infant, Newborn, Hypoxia-Ischemia, Brain
Interventions: Induced hypothermia, Control; Device
Lead sponsor: NICHD Neonatal Research Network; Network
Eligibility: Up to 6 Hours
Enrollment: 208 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2010
U.S. locations: 16
States / cities: Birmingham, Alabama • Palo Alto, California • New Haven, Connecticut + 13 more

Conditions: Pervasive Development Disorders
Interventions: placebo, extended-release guanfacine; Other · Drug
Lead sponsor: Yale University; Other
Eligibility: 5 Years to 14 Years
Enrollment: 62 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 5
States / cities: Los Angeles, California • New Haven, Connecticut • Atlanta, Georgia + 2 more

Conditions: Bipolar Depression
Interventions: Olanzapine Fluoxetine Combination (OFC), Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 10 Years to 17 Years
Enrollment: 291 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 1
States / cities: San Diego, California

Conditions: Epilepsy
Interventions: Empagliflozin 25 mg, Placebo; Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years to 45 Years
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Parkinson's Disease
Interventions: Rasagiline, Placebo; Drug
Lead sponsor: The Parkinson's Institute; Other
Eligibility: Up to 90 Years
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2014
U.S. locations: 1
States / cities: Sunnyvale, California

Conditions: Diabetic Nephropathy
Interventions: SPP301; Drug
Lead sponsor: Speedel Pharma Ltd.; Industry
Eligibility: 21 Years to 80 Years
Enrollment: 2,364 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 1
States / cities: Greenville, North Carolina

Conditions: Parkinson's Disease, Gait Impairment
Interventions: Methylphenidate (MPD), Placebo; Drug
Lead sponsor: University of Cincinnati; Other
Eligibility: 35 Years to 85 Years
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 1
States / cities: Cincinnati, Ohio

Search by objective public record fields.

A 12-week Study to Evaluate the Efficacy and Safety of Umeclidinium Compared With Tiotropium in Subjects With Chronic Obstructive Pulmonary Disease

Efficacy and Safety of an Oral Growth Hormone Drug in the Treatment of Fibromyalgia

Ubenimex in Adult Patients With Lymphedema of The Lower Limb (ULTRA)

Long-term Safety, Curvature Deformity Characterization, and Immunogenicity Over Time in Subjects Previously Treated With AA4500 for Peyronies Disease

Efficacy, Safety and Tolerability of Agomelatine Sublingual Tablets in the Treatment of Major Depressive Disorder (MDD)

VELVET, a Dose Range Finding Trial of Veltuzumab in Subjects With Moderate to Severe Rheumatoid Arthritis

A Clinical Trial of MK-6916 in Participants With Pain After Bunion Removal Surgery (MK-6916-007)

Minimal Breathing Support and Early Steroids to Prevent Chronic Lung Disease in Extremely Premature Infants (SAVE)

Mitigating Toxic Impact: The Role of Coenzyme Q10 in Post-Exposure Protection

Staccato Loxapine in Migraine (Out Patient)

Use of Autologous Bone Marrow Aspirate Concentrate in Painful Knee Osteoarthritis

Allogeneic ABCB5-positive Dermal Mesenchymal Stromal Cells for Treatment of Epidermolysis Bullosa (Phase III)

Study of CD388 Subcutaneous Administration in Healthy Japanese Subjects

Study GSI-136 in Healthy Young and Healthy Elderly Subjects

Copper IUD Treatment Observation Study

Doxazosin for Psychostimulant Dependence

Sleep Disordered Breathing With Opioid Use

Whole-Body Cooling for Birth Asphyxia in Term Infants

Guanfacine for the Treatment of Hyperactivity in Pervasive Developmental Disorder

A Study for Assessing Treatment of Patients Ages 10-17 With Bipolar Depression

Sodium-Glucose Cotransporter-2 Inhibitors: A Potential Novel Treatment for Epilepsy

A Study Assessing Change in Sense of Smell After Rasagiline Use in Parkinson's Patients

To Determine the Effects of Avosentan on Doubling of Serum Creatinine, End Stage Renal Disease and Death in Diabetic Nephropathy

Methylphenidate for the Treatment of Gait Impairment in Parkinson's Disease